
Opinion|Videos|August 14, 2024
Optimizing Anemia Management and Addressing Unmet Needs in LR MDS
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series

- Please share your key takeaways for optimizing anemia management in lower-risk MDS, and where do you see the most significant unmet needs?
- What remain the key unmet needs in treating anemia and improving outcomes for lower-risk MDS patients despite the availability of therapies like imetelstat, luspatercept, and ESAs?
- Are there any emerging agents, combination regimens, or ongoing trials in the pipeline?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















